Anti-Human CD30/TNFRSF8 Reference Antibody (XmAb 2513)

Description: Anti-Human CD30/TNFRSF8 (XmAb 2513) (BS11078) is a research-grade recombinant antibody targeting CD30L. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Human
Isotype: IgG
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: CD30Lreceptor,Ki-1antigen,CD30,TNFRSF8,D1S166E,Tumornecrosisfactorreceptorsuperfamilymember8,LymphocyteactivationantigenCD30
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: XmAb-2513,XmAb2513,XmAb2513
Background: Tumor necrosis factor receptor superfamily member 8 (CD30/TNFRSF8) is a ~63 kDa protein. Receptor for TNFSF8/CD30L. May play a role in the regulation of cellular growth and transformation of activated lymphoblasts. Regulates gene expression through activation of NF-kappa-B. CD30 is the therapeutic target of brentuximab vedotin (Adcetris).
References:
1. Smith, CA. et al. (1993) Cell 73, 1349-60. PMID: 8391931
2. Aizawa, S. et al. (1997) The Journal of biological chemistry 272, 2042-5. PMID: 8999898
Note: For research use only. Not suitable for clinical or therapeutic use.